The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...